PARPi Use Associated With Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer
The researchers noted that the objective of the study was to assess the trends of 1L PARPi maintenance treatment uptake and PFS of patients with newly diagnosed AOC.
A recent real-world analysis showed that the adoption of PARPi mono in the first-line (1L) maintenance setting in patients with newly diagnosed advanced ovarian cancer (AOC) has increased to 53% in 2021. Additionally, the use of PARPi when compared with active surveillance (AS) was found to be connected with significantly improved median progression-free survival (mPFS) in both patients with BRCA mutations (BRCAm) and BRCA wild type (BRCAwt), according to researchers in a session presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
The researchers noted that the objective of the study was to assess the trends of 1L PARPi maintenance treatment uptake and PFS of patients with newly diagnosed AOC. The researchers analysed data pertaining to patients who were diagnosed with AOC between January 1, 2017 and June 30, 2021 and who completed 1L chemotherapy. These patients were identified from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database.
The researchers calculated the statistics by describing patient demographics, clinic-pathological characteristics, and 1L treatment patterns. Further, they identified the use of PARPi or active surveillance (AS) during a 120-day period after the last dose of 1L chemotherapy.
The results showed that among the 705 patients included in the study, 166 received PARPi monotherapy and 539 underwent AS after completion of 1L chemotherapy. Overall, median PFS was 9.53 months for AS versus not reached for PARPi monotherapy. In patients with BRCAm, corresponding mPFS was 11.4 months versus not reached and for BRCAwt was 9.1 months versus 13.5 months.
Additionally, on a multivariate analysis, 1L PARPi maintenance was an independent predictor for improved PFS when compared to AS in all patients, BRCAm, and BRCAwt. The trends over the 4-year study period showed PARPi monotherapy use increased from 6% in 2017 to 53% in 2021.
Chan JK, Liu J, Song J, et al. Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States. 2022 ASCO Annual Meeting. Accessed June 6, 2022. 10.1200/JCO.2022.40.16_suppl.6580